carbostyril has been researched along with Metastase in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (21.21) | 29.6817 |
| 2010's | 23 (69.70) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Brose, M; Chau, NG; Cohen, EEW; Gualberto, A; Guenette, JP; Hanna, GJ; Ho, AL; Metcalf, R; Pérez-Ruiz, E; Razaq, M; Sayehli, CM; Scholz, C; Wilhelm, C; Wong, DJ | 1 |
| Choi, HY; Gualberto, A; Jeong, BC; Kwon, GY; Lee, HW; Park, SH; Sa, JK; Scholz, C; Sung, HH | 1 |
| Dean, DC; Duan, Z; Hornicek, FJ; Nelson, SD; Thanindratarn, P | 1 |
| Dillon, PM; Douvas, MG; Fracasso, PM; Horton, BJ; Moskaluk, CA; Petroni, GR; Thomas, CY; Varhegyi, N; Zaja-Milatovic, S | 1 |
| Choi, YJ; Kim, BS; Kim, HG; Kim, HS; Kim, KH; Lee, HJ; Lee, HY; Lee, JL; Lee, KH; Park, KH; Park, SH; Shin, DY; Song, HS | 1 |
| Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W | 1 |
| Banik, P; Bharti, R; Chakraborty, S; Das, SK; Dey, G; Dey, KK; Emdad, L; Fisher, PB; Ghosh, SK; Kundu, SC; Mandal, M; Naskar, D; Pal, I; Rajesh, Y | 1 |
| Adil, MS; Alwhaibi, A; Artham, S; Somanath, PR; Verma, A | 1 |
| Armstrong, AJ; Assikis, V; Belkoff, L; Carducci, MA; Damber, JE; Forsberg, G; Gingrich, JR; Häggman, M; Nordle, Ö; Pili, R; Polikoff, J; Stadler, WM | 1 |
| Bjarnason, GA; Cai, C; Davis, ID; De Giorgi, U; Escudier, B; Esteban, E; Grünwald, V; Kollmannsberger, C; Lee, JL; Marker, M; Melichar, B; Motzer, RJ; Porta, C; Rha, SY; Shi, MM; Squires, M; Sternberg, CN; Szczylik, C; Urbanowitz, G; Vogelzang, NJ; Zolnierek, J | 1 |
| Angevin, E; Beall, S; Castellano, D; Escudier, B; Grünwald, V; Gschwend, JE; Harzstark, A; Lin, CC; Ou, YC; Pirotta, N; Ravaud, A; Shi, M; Squires, M | 1 |
| Bajorin, D; Cerbone, L; Dittrich, C; Durán, I; Jagdev, S; Lochheed, M; Millard, FE; Milowsky, MI; Quinn, DI; Rosenberg, JE; Sen, P; Shi, M; Squires, M; Stadler, WM; Sternberg, CN; Sweeney, CJ | 1 |
| Bang, YJ; Cho, BC; Keam, B; Kim, MK; Kim, SB; Lee, KW; Lee, SH; Shin, SH; Yoon, DH; Yun, HJ | 1 |
| Finkler, N; Fong, PC; Garcia, AA; Konecny, GE; Kristeleit, R; Lee, PS; Lorusso, D; Mishra, K; Rocconi, RP; Squires, M; Upalawanna, A; Wang, Y | 1 |
| Das, M; Frymoyer, A; Neal, JW; Padda, SK; Riess, JW; Wakelee, HA; Zhou, L | 1 |
| Damber, JE; Hagberg Thulin, M; Magnusson, LU; Olsson, A; Plas, P; Welén, K | 1 |
| Feng, Q; Gao, T; Lei, Q; Shi, Y; Song, X; Wang, N; Wei, Y; Xia, Y; Xiong, M; Yang, F; Ye, T; You, X; Yu, L; Zhang, L; Zhu, Y | 1 |
| Agarwal, N; Armstrong, A; Baton, F; Bögemann, M; Brize, A; Carducci, M; Chowdhury, S; Delva, R; Gallardo, E; Harza, M; Huddart, R; Hutson, T; James, N; Khvorostenko, D; Lyulko, O; Milecki, P; Nederman, T; Ng, S; Pili, R; Pouget, JC; Schwartsmann, G; Sternberg, C; Thanos, A; Tuvesson, H; Vogelzang, N; Werbrouck, P | 1 |
| André, F; Barrios, CH; Blackwell, K; Bonnefoi, H; Campone, M; Cortes, J; Denduluri, N; Deudon, S; Kahan, Z; Musolino, A; Neven, P; Shi, MM; Soliman, H; Squires, M; Zhang, Y | 1 |
| Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
| Allal, BC; Chaoui, K; Dalenc, F; Doisneau-Sixou, SF; Favre, G; Filleron, T; Lauwers-Cances, V; Malissein, E; Marsili, S; Meunier, E; Monsarrat, B; Renée, N; Roché, H; Schiltz, O | 1 |
| Chung, JG; Hsu, SC; Huang, CC; Ip, SW; Kuo, CL; Kuo, SC; Lai, KC; Lai, TY; Lin, SY; Wood, WG; Yang, JS | 1 |
| Bernhard, JC; De Clermont, H; Gross-Goupil, M; Quivy, A; Ravaud, A; Roca, S | 1 |
| Armstrong, AJ; Assikis, VJ; Björk, A; Carducci, MA; Forsberg, G; Gingrich, JR; Häggman, M; Nordle, O; Pili, R; Stadler, WM | 1 |
| Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA | 1 |
| Axelsson, B; Damber, JE; Jennbacken, K; Leanderson, T; Olsson, A; Törngren, M; Welén, K | 1 |
| Chen, ZY; Guo, RP; Guo, ZX; Li, SH; Li, XJ; Peng, LX; Qian, CN; Shi, M; Wei, W; Zhong, C | 1 |
| Li, T; Sparano, JA | 1 |
| Abbruzzese, JL; Alpaugh, RK; Beard, M; Cohen, SJ; Ho, L; Hudes, GR; Lewis, NL; McLaughlin, S; Meropol, NJ; Perez-Ruixo, JJ; Ranganathan, S; Rogatko, A; Thistle, AM; Verhaeghe, T; Wang, H; Weiner, LM; Wright, JJ | 1 |
| Dowsett, M; Ellis, P; Hickish, T; Houston, S; Howes, A; Johnston, SR; Kelland, L; Michiels, B; Palmer, P; Perez-Ruixo, JJ; Salter, J | 1 |
| Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
| Chang, YL; Guh, JH; Huang, DY; Kuo, SC; Lee, KH; Pan, SL; Peng, CY; Teng, CM; Tsai, AC; Wang, SW | 1 |
| Andela, VB; O'Keefe, RJ; Puzas, EJ; Rosenblatt, JD; Rosier, RN; Schwarz, EM | 1 |
1 review(s) available for carbostyril and Metastase
| Article | Year |
|---|---|
Inhibiting Ras signaling in the therapy of breast cancer.
Topics: Alkyl and Aryl Transferases; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Female; GTP-Binding Proteins; Humans; Mutation; Neoplasm Metastasis; Quinolones; ras Proteins; Signal Transduction | 2003 |
21 trial(s) available for carbostyril and Metastase
| Article | Year |
|---|---|
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Quinolones; Salivary Gland Neoplasms; Treatment Outcome | 2020 |
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Topics: Aged; AMP-Activated Protein Kinase Kinases; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinolones; Urothelium | 2020 |
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Topics: Adult; Aged; Benzimidazoles; Carcinoma, Adenoid Cystic; Cell Proliferation; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncogene Proteins v-myb; Quinolones; Receptor, Fibroblast Growth Factor, Type 1 | 2017 |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome | 2018 |
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone Neoplasms; C-Reactive Protein; Disease-Free Survival; Humans; L-Lactate Dehydrogenase; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Survival Analysis; Vascular Endothelial Growth Factor A | 2013 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fibroblast Growth Factor-23; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy | 2014 |
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzimidazoles; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinolones; Receptor, Fibroblast Growth Factor, Type 3; Treatment Outcome; Urologic Neoplasms | 2014 |
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Adenoid Cystic; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Republic of Korea; Salivary Gland Neoplasms; Treatment Outcome; Young Adult | 2015 |
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Treatment Outcome | 2015 |
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinolones; Receptors, Vascular Endothelial Growth Factor; Retreatment; Treatment Outcome | 2015 |
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinolones | 2016 |
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Survival Analysis; Treatment Outcome | 2017 |
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Protein Array Analysis; Quinolones; Tamoxifen | 2010 |
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Calgranulin B; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prostatic Neoplasms; Quinolines; Quinolones | 2011 |
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Carrier Proteins; Disease Progression; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinolones; Treatment Outcome | 2003 |
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinolones; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
11 other study(ies) available for carbostyril and Metastase
| Article | Year |
|---|---|
T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chordoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinolones; RNA Interference; RNA, Small Interfering; Thiophenes | 2020 |
Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis.
Topics: Antigens, CD; Antineoplastic Agents; Benzimidazoles; beta Catenin; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Proto-Oncogene Proteins c-akt; Quinolones; Transforming Growth Factor beta; Vinculin | 2019 |
Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.
Topics: Animals; Benzodioxoles; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Forkhead Box Protein O3; Gene Silencing; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Nodal Protein; PC-3 Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyridines; Quinolones; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cytokines; Heterografts; Humans; Immune Tolerance; Inflammation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Osteoblasts; Osteogenesis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Tibia; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Female; Histones; Humans; Intracellular Space; Methylation; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Polycomb Repressive Complex 2; Pyridones; Quinolones; Small Molecule Libraries; Transcriptional Activation; Xenograft Model Antitumor Assays | 2016 |
2-(3-Methoxyphenyl)-6, 7-methylenedioxoquinolin-4-one, a novel synthetic compound, inhibited migration and invasion in TSGH8301 human bladder cancer cells.
Topics: Antineoplastic Agents; Benzodioxoles; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase Inhibitors; Molecular Structure; Neoplasm Invasiveness; Neoplasm Metastasis; Quinolones | 2011 |
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Quinolones; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Down-Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Nude; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Quinolines; Quinolones; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Topics: Animals; Apoptosis; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinolones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dioxoles; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; I-kappa B Kinase; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Models, Biological; Models, Chemical; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Phosphorylation; Quinolones | 2007 |
Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Flow Cytometry; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Quinolones; Tumor Cells, Cultured | 2002 |